Drug intelligence / Profile preview

S1PR1 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Local (e.g., Direct Injection Into Tissue Or Organ, As In Preclinical Models)[2][4], Not Established For Systemic Clinical Use
01

Overview

S1PR1 siRNA is a **small interfering RNA** specifically designed to bind and degrade the messenger RNA of **Sphingosine-1-phosphate receptor 1 (S1PR1/EDG1)**, effectively silencing the expression of this G-protein-coupled receptor. S1PR1 is involved in the regulation of immune cell trafficking, vascular growth, and neuronal excitability. Knocking down S1PR1 with siRNA has been shown to reduce S1PR1 protein expression, suppress inflammatory responses, and inhibit processes such as angiogenesis, tumor growth, neuroinflammation, and nociceptive pain signaling[2][3][4]. Experimental use of S1PR1 siRNA demonstrates its ability to modulate disease states by preventing S1PR1-mediated cellular activation and subsequent pro-inflammatory and pro-nociceptive effects[2][3][4]. S1PR1 siRNA is primarily used as a research tool, notably in preclinical studies of pain, inflammation, neurobiology, vascular biology, and cancer.

Brand names
S1PR1 siRNAS-1PR1 siRNAS 1PR1 siRNA
Other names
S1PR1-targeting small interfering RNAS-1PR1-targeting small interfering RNAS 1PR1-targeting small interfering RNAsiRNA against S1P receptor 1
02

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on S1PR1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1PR1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call